Known targets — ChEMBL curated mechanism
GRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5
The experimentally established mechanism targets of Tezampanel Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 known ✓ | P42261 | 3/20 | 0.65 |
| ▸ | GRIA2 known ✓ | P42262 | 3/20 | 0.65 |
| ▸ | GRIA3 known ✓ | P42263 | 3/20 | 0.65 |
| ▸ | GRIA4 known ✓ | P48058 | 3/20 | 0.65 |
| ▸ | GRIK1 known ✓ | P39086 | 1/20 | 0.65 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.65 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.65 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.65 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.65 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.65 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.65 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tezampanel Anhydrous SCHEMBL3677003 | 1.00 | GRIA1 (0.65) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| Tezampanel Anhydrous SCHEMBL29227429 | 1.00 | GRIA1 (0.65) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| Tezampanel Anhydrous SCHEMBL13320011 | 1.00 | GRIA1 (0.65) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| Tezampanel Anhydrous SCHEMBL3227089 | 1.00 | GRIA1 (0.65) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| Tezampanel Anhydrous SCHEMBL3688367 | 1.00 | GRIA1 (0.65) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| Tezampanel Anhydrous SCHEMBL5508469 | 0.99 | GRIA1 (0.64) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| SCHEMBL14179393 | 0.90 | GRIA1 (0.53) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| SCHEMBL2783303 | 0.88 | GRIA2 (0.64) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| SCHEMBL8867563 | 0.88 | GRIA2 (0.64) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| SCHEMBL20553364 | 0.88 | GRIA2 (0.64) | GRIA1GRIA2GRIA3GRIA4GRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3160464-A1 | USE OF BUSPIRONE METABOLITES | Contera Pharma APS (DK) | 2017-05-03 | — | — | EP | claimed |
| WO-2015197079-A1 | USE OF BUSPIRONE METABOLITES | CONTERA PHARMA APS (DK) | 2015-12-30 | — | — | WO | claimed |
| US-20040152694-A1 | Methods and compositions for treating inflammatory disorders of the airways | IVAX DRUG RESEARCH INSTITUTE, LTD. | 2004-08-05 | — | — | US | claimed |
| EP-4175635-B1 | PHARMACEUTICAL COMPOSITIONS OF 6-(2-(2H-TETRAZOL-5-YL)ETHYL)-6-FLUORODECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID AND ESTER DERIVATIVES THEREOF | SEA PHARMACEUTICALS LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20250281474-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING COGNITIVE DECLINE OR FOR TREATING OVERWEIGHTNESS OR OBESITY | UNIVERSITY OF THE RYUKYUS (JP) | 2025-09-11 | — | — | US | disclosed |
| US-20250074887-A1 | PHARMACEUTICAL COMPOSITIONS OF 6-(2-(2H-TETRAZOL-5-YL)ETHYL)DECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID AND DERIVATIVES THEREOF | Sea Pharmaceuticals LLC. (US) | 2025-03-06 | — | — | US | disclosed |
| US-20240398775-A1 | PHARMACEUTICAL COMPOSITION FOR USE IN TREATING COGNITIVE DECLINE OR FOR USE IN TREATING OVERWEIGHT OR OBESITY | UNIVERSITY OF THE RYUKYUS (JP) | 2024-12-05 | — | — | US | disclosed |
| US-20240277697-A1 | METHODS OF TREATING OR PREVENTING CONDITIONS ASSOCIATED WITH OPIATE WITHDRAWAL OR OPIATE RELAPSE | PRONIRAS CORPORATION | 2024-08-22 | — | — | US | disclosed |
| US-20240277696-A1 | METHODS OF TREATING NERVE AGENT-INDUCED SEIZURES | PRONIRAS CORPORATION | 2024-08-22 | — | — | US | disclosed |
| EP-4403185-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING COGNITIVE DECLINE OR FOR TREATING OVERWEIGHTNESS OR OBESITY | University of The Ryukyus (JP) | 2024-07-24 | — | — | EP | disclosed |
| EP-4403184-A1 | PHARMACEUTICAL COMPOSITION FOR USE IN TREATING COGNITIVE DECLINE, EXCESS WEIGHT, OR OBESITY | University of The Ryukyus (JP) | 2024-07-24 | — | — | EP | disclosed |
| US-20100144868-A1 | Novel Neuroprotective Compounds and Uses Thereof | RAMOT AT AVIV UNIVERSITY LTD. (IL) | 2010-06-10 | — | — | US | disclosed |
| US-20100144868-A1 | Novel Neuroprotective Compounds and Uses Thereof | RAMOT AT AVIV UNIVERSITY LTD. (IL) | 2010-06-10 | — | — | US | disclosed |
| EP-2150248-A2 | GLUTAMATE RECEPTOR ANTAGONISTS AND METHODS OF USE | The Johns Hopkins University (US) | 2010-02-10 | — | — | EP | disclosed |
| WO-2008088820-A2 | GLUTAMATE RECEPTOR ANTAGONISTS AND METHODS OF USE | THE JOHNS HOPKINS UNIVERSITY (US) | 2008-07-24 | — | — | WO | disclosed |
| EP-1829539-A2 | A method for treating tension-type headache | HEADEXPLORER ApS (DK) | 2007-09-05 | — | — | EP | disclosed |
| US-7247644-B2 | Ester derivatives of a decahydroisoquinoline-3-carboxylic acid as analgestics | ELI LILLY AND COMPANY (US) | 2007-07-24 | — | — | US | disclosed |
| US-7247644-B2 | Ester derivatives of a decahydroisoquinoline-3-carboxylic acid as analgestics | ELI LILLY AND COMPANY (US) | 2007-07-24 | — | — | US | disclosed |
| US-20040097562-A1 | Method for treating tension-type headache | HEAD EXPLORER APS (DK) | 2004-05-20 | — | — | US | disclosed |
| US-6399639-B1 | ADMINISTERING A 2,4-THIADIAZOLIDINEDIONE COMPOUND | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240277697-A1 | METHODS OF TREATING OR PREVENTING CONDITIONS ASSOCIATED WITH OPIATE WITHDRAWAL OR OPIATE RELAPSE | TPMT, OPRK1, OPRL1 | GRIA1 633/4885GRIA2 1005/4885GRIA3 474/4885 |
| US-20250074887-A1 | PHARMACEUTICAL COMPOSITIONS OF 6-(2-(2H-TETRAZOL-5-YL)ETHYL)DECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID AND DERIVATIVES THEREOF | GABRQ, GRIK5, CYP3A7 | GRIA1 1021/4885GRIA2 460/4885GRIA3 298/4885 |
| US-20040152694-A1 | Methods and compositions for treating inflammatory disorders of the airways | LTB4R2, LTB4R, LTC4S | GRIA1 2085/4885GRIA2 2341/4885GRIA3 2201/4885 |
| US-20100144868-A1 | Novel Neuroprotective Compounds and Uses Thereof | GRM2, GRIN1, GRM3 | GRIA1 22/4885GRIA2 21/4885GRIA3 18/4885 |
| US-20240277696-A1 | METHODS OF TREATING NERVE AGENT-INDUCED SEIZURES | PMP22, GAP43, GABBR1 | GRIA1 835/4885GRIA2 698/4885GRIA3 402/4885 |
| US-20040097562-A1 | Method for treating tension-type headache | GRIN3A, GRIN2A, GRIK4 | GRIA1 26/4885GRIA2 19/4885GRIA3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.